Induction of Migraine Aura With Cilostazol

Herlev Hospital

Status and phase: Completed; Early Phase 1

Conditions: Migraine With Aura; Stroke

Treatments: Drug: Placebo; Drug: Cilostazol

Study type: Interventional

Funder types: Other

Identifiers

NCT02253004

2013-004188-29 (EudraCT Number)

H-3-2013-166

Details and patient eligibility

About

In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

Full description

Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.

Enrollment: 16 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Migraine with aura
• Minimum of 2 attacks/year

Exclusion criteria

• Chronic tension type headache
• Cardiac arrhythmias

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

16 participants in 2 patient groups, including a placebo group

Active

Experimental group

Description:

Cilostazol 200 mg single dose

Treatment:

Drug: Cilostazol

Placebo

Placebo Comparator group

Description:

Placebo capsule

Treatment:

Drug: Placebo